| Literature DB >> 31810882 |
William H Hudson1, Julia Gensheimer1, Masao Hashimoto1, Andreas Wieland1, Rajesh M Valanparambil1, Peng Li2, Jian-Xin Lin2, Bogumila T Konieczny1, Se Jin Im1, Gordon J Freeman3, Warren J Leonard2, Haydn T Kissick4, Rafi Ahmed5.
Abstract
T cell dysfunction is a characteristic feature of chronic viral infection and cancer. Recent studies in chronic lymphocytic choriomeningitis virus (LCMV) infection have defined a PD-1+ Tcf-1+ CD8+ T cell subset capable of self-renewal and differentiation into more terminally differentiated cells that downregulate Tcf-1 and express additional inhibitory molecules such as Tim3. Here, we demonstrated that expression of the glycoprotein CD101 divides this terminally differentiated population into two subsets. Stem-like Tcf-1+ CD8+ T cells initially differentiated into a transitory population of CD101-Tim3+ cells that later converted into CD101+ Tim3+ cells. Recently generated CD101-Tim3+ cells proliferated in vivo, contributed to viral control, and were marked by an effector-like transcriptional signature including expression of the chemokine receptor CX3CR1, pro-inflammatory cytokines, and granzyme B. PD-1 pathway blockade increased the numbers of CD101-Tim3+ CD8+ T cells, suggesting that these newly generated transitional cells play a critical role in PD-1-based immunotherapy.Entities:
Keywords: CD101; CD8(+) T cells; CX3CR1; LCMV; PD-1; T cell differentiation; checkpoint blockade; chronic viral infection; exhaustion; immunotherapy
Mesh:
Substances:
Year: 2019 PMID: 31810882 PMCID: PMC6920571 DOI: 10.1016/j.immuni.2019.11.002
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745